The United States' efforts to reduce drug prices may have an unexpected consequence for European patients: longer waiting times for access to some innovative treatments.
Trump's measure to make medicines cheaper in the US may affect the availability of new treatments in Europe. Scientists warn that American policy may have repercussions beyond the borders of the United States.
European patients may face longer waiting times to access innovative treatments if Trump's measure proceeds. This situation arises as a potential result of changes in American pharmaceutical policy.



